Table 5.
Association between SNPs in OSMR and patient’s survival
| SNP/genotype | NMIBC | MIBC | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alive/dead | HR (95% CI) a | P | Recurrence/Non-recurrence | HR (95% CI) b | P | Alive/dead | HR (95% CI) a | P | Recurrence/Non-recurrence | HR (95% CI) b | P | |
| rs2278329 | ||||||||||||
| GG | 63/8 | 16/55 | 46/16 | 6/8 | ||||||||
| GA | 70/3 | 25/48 | 49/17 | 20/46 | ||||||||
| AA | 19/1 | 4/16 | 11/3 | 18/44 | ||||||||
| Dominant | 0.31 (0.09–1.06) | 0.06 | 1.56 (0.0.84–2.89) | 0.16 | 1.14 (0.57–2.26) | 0.71 | 1.05 (0.56–1.96) | 0.88 | ||||
| Recessive | 0.77 (0.10–6.10) | 0.80 | 0.49 (0.17–1.39) | 0.18 | 1.10 (0.31–3.94) | 0.88 | 1.54 (0.60–3.97) | 0.37 | ||||
| Overdominant | 0.31 (0.08–1.20) | 0.09 | 2.16 (1.17–3.98) | 0.01 | 1.10 (0.57–2.13) | 0.78 | 0.89 (0.49–1.63) | 0.71 | ||||
| rs2292016 | ||||||||||||
| GG | 66/9 | 15/60 | 48/13 | 15/46 | ||||||||
| GT | 66/3 | 23/46 | 47/19 | 24/42 | ||||||||
| TT | 20/0 | 7/13 | 11/4 | 5/10 | ||||||||
| Dominant | 0.22 (0.06–0.86) | 0.029 | 1.74 (0.92–3.27) | 0.08 | 1.36 (0.69–2.70) | 0.38 | 1.45 (0.78–2.72) | 0.24 | ||||
| Recessive | NA (0–NA) | 0.98 | 1.18 (0.51–2.71) | 0.70 | 1.21 (0.43–3.52) | 0.72 | 1.12 (0.36–2.88) | 0.82 | ||||
| Overdominant | 0.37 (0.09–1.43) | 0.15 | 1.58 (0.86–2.90) | 0.14 | 1.25 (0.65–2.43) | 0.50 | 1.37 (0.75–2.52) | 0.30 | ||||
N corresponds to the number of individuals
aAdjusted by age, sex, smoking status, tumor stage, and recurrence
bAdjusted by age, sex, smoking status, and tumor stage. Italicized values indicate a significant difference at the 5% level